Novozymes A/S v DSM IP Assets B.V

Link copied
Case Copied 13 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Novozymes A/S v DSM IP Assets B.V. [2018] APO 2

Patent Application:                2010270301

Title:Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain

Patent Applicant:                   DSM IP Assets B.V.

Opponent:  Novozymes A/S

Hearing Officer:  Dr S.D. Barker – Deputy Commissioner of Patents

Decision Date:  5 January 2018

Hearing Date:  29 November 2017, in Canberra

Catchwords:  PATENTS – opposition to the grant of a patent – where an opposition is decided in stages, findings of fact in the original decision must be applied in the final determination – original decision found lack of inventive step – this ground has been overcome consistent with the original decision – application proceed to grant

Representation:  Counsel for the applicant:  Mr B Fitzpatrick

Patent attorney for the applicant:  Mr D Longmuir of Phillips Ormonde Fitzpatrick

Counsel for the opponent:  Ms K Crooks

Patent attorney for the opponent:  Dr J Flattery-O'Brien of Shelston IP Pty Ltd

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2010270301

Title:Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain

Patent Applicant:                   DSM IP Assets B.V.

Date of Decision:                   5 January 2018

DECISION

I direct that the application proceed to grant.

I allow the parties an opportunity to provide written submissions in relation to costs according to the following schedule:

DSM IP Assets B.V. is to provide submissions within three (3) weeks from the date of this decision;
Novozymes A/S is to provide submissions in response within five (5) weeks of the date of this decision;
DSM IP Assets B.V. is to provide a reply (if any) within six (6) weeks of the date of this decision.

REASONS FOR DECISION

  1. Patent application number 2010270301 (the present application) was filed on 6 July 2010 under the provisions of the Patent Cooperation Treaty.  The applicant is DSM IP Assets B.V. (DSM).  An opposition to the grant of a patent was filed by Novozymes A/S (Novozymes).  A decision issued on 17 January 2017 (the original decision). [1]  The applicant was given an opportunity to amend, and the amendments have been allowed.  The opponent asked to be heard in the final determination of the opposition, and a hearing was held on 29 November 2017 in Canberra. 

    The original decision

  2. The original decision found that claims 1 – 11, 13, 14 and 16 lack inventive step in the light of a document referred to as YJ-9.  It is to be noted that there was no finding that claim 12 lacked inventive step.  Rather, there was an explicit finding that it had not been shown that claim 12 lacked inventive step:

    "Claim 12 is appended to claim 11.  The claim specifies that the cell is an inhibitor resistant cell.  YJ-9 makes no reference to the cell being inhibitor resistant.  There is no evidence that this would have been a matter of routine.  It follows that…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novozymes A/S v DSM IP Assets B.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] APO 2
Decision Date

CaseChat Overview and Summary

Novozymes A/S opposed the grant of patent application 2010270301 filed by DSM IP Assets B.V. The opposition was decided in stages, with an initial decision finding that claims 1 – 11, 13, 14 and 16 of the patent application lacked inventive step. The patent applicant was allowed to amend the specification and, following amendment, the opposition proceeded to a final determination. The court had to decide whether the amendments overcome the deficiencies identified in the original decision, and whether the amendments introduce any new deficiencies.

The court considered the legal principles governing the final determination of an opposition decided in stages. It found that a final determination could only consider whether the amendments overcome the deficiencies identified in the original decision, and whether the amendments introduce any new deficiencies. The final determination should be consistent with any relevant findings in the original decision. The court found that the amendments had overcome the deficiencies identified in the original decision, and had not introduced any new deficiencies.

The court found that claim 1 as amended was not lacking in inventive step because the use of an inhibitor resistant cell would not have been a matter of routine. Claims 3 – 13 and claim 24, which were appended to claims 1 or 2, also did not lack inventive step for the same reason. The court found that the amendment had not introduced any new deficiencies.

The court directed the parties to provide written submissions in relation to costs. DSM was to provide submissions within three weeks of the date of the decision, Novozymes was to provide submissions in response within five weeks of the date of the decision, and DSM was to provide a reply within six weeks of the date of the decision. The patent application proceeded to grant.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.